Health-related Quality of Life in RRMM Patients Treated with Ide-Cel vs Belantamab Mafodotin (https://www.myeloma.org/videos/health-related-quality-life-rrmm-patients-treated-ide-cel-vs-belantamab-mafodotin)
Matching-Adjusted Indirect Comparison Study: Health-related Quality of Life in RRMM Patients Treated with Ide-Cel vs Belantamab Mafodotin Presented at EHA 2022
Dr.Nina Shah Discusses Health-related Quality of Life in RRMM Patients Treated with Idecabtagene Vicleucel (Ide-Cel) vs Belantamab Mafodotin in Matching-Adjusted Indirect Comparison Study
Abstract Title:
Health-related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Idecabtagene Vicleucel vs Belantamab Mafodotin: A Matching-Adjusted Indirect Comparison Study
What is the purpose of this trial?
To compare health-related quality of life outcomes for triple-class exposed (TCE) relapsed/refractory multiple myeloma patients treated with ide-cel vs belantamab mafodotin.
RRMM patients who are triple-class exposed (TCE) to an immunomodulatory imide drug (IMiD® agent), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb) have poor clinical outcomes and poor health-related quality of life (HRQoL). The B-cell maturation antigen (BCMA)-directed CAR T cell therapy idecabtagene vicleucel (ide-cel, bb2121) received regulatory approval in the US for patients with RRMM with ≥4 prior lines of therapy (LOT), including an IMiD agent, PI, and anti-CD38 mAb, and in Europe and Japan for patients with RRMM with ≥3 prior LOTs including an IMiD agent, PI, and anti-CD38 mAb.
Ide-cel showed frequent, deep, and durable responses in TCE pts with RRMM in KarMMa, a phase 2, single-arm trial. Clinically meaningful improvements in HRQoL outcomes vs baseline were observed.
The BCMA-targeted antibody-drug conjugate belantamab mafodotin was approved in the US and Europe for patients with RRMM with ≥4 prior LOTs including an IMiD agent, PI and anti-CD38 mAb, based on data from the phase 2, single-arm DREAMM-2 trial. There is a paucity of evidence comparing HRQoL for different treatment options approved in RRMM.
In this video:
Dr.Nina Shah (UCSF Helen Diller Family Comprehensive Cancer Center—San Francisco, CA) discusses health-related quality of life (HRQoL) in relapsed/refractory mulitple myeloma (RRMM) patients treated with ide-cel vs belantamab mafodotin in matching-adjusted indirect comparison study.
Conclusion:
While this analysis was limited by the availability of aggregate data from DREAMM-2, which may influence the outcomes of interest, results suggest that one-time treatment with ide-cel offers improved HRQoL vs belantamab mafodotin across the EORTC quality of life questionnaire (QLQ-C30) pain, fatigue, and global health status/QoL domains, as well as the QLQ-MY20 pain domain.
Clinical trial information: NCT03361748, NCT03525678
Doctor Bio:
Dr. Nina Shah is a clinical professor and a hematologist who specializes in the treatment of multiple myeloma. She treats patients at the Hematology and Blood Marrow and Transplant Clinic at UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, CA.
Dr. Shah’s areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems.
Shah belongs to the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology